HIV rapid tests: progress, perspective, and future directions.
In November 2002, the U.S. Food and Drug Administration approved the OraQuick Rapid HIV-1 Antibody Test (OraSure Technologies, Inc., Bethlehem, PA), a reliable, rapid test that detects HIV-1 antibodies. In contrast to other HIV-testing techniques, the OraQuick test uses blood obtained by finger stic...
| Publicado en: | Clinical Journal of Oncology Nursing Vol. 7; no. 2; pp. 207 - 209 |
|---|---|
| Autor principal: | |
| Formato: | tables/charts Journal Article |
| Publicado: |
Oncology Nursing Society
Mar/Apr2003
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | In November 2002, the U.S. Food and Drug Administration approved the OraQuick Rapid HIV-1 Antibody Test (OraSure Technologies, Inc., Bethlehem, PA), a reliable, rapid test that detects HIV-1 antibodies. In contrast to other HIV-testing techniques, the OraQuick test uses blood obtained by finger stick instead of venipuncture and provides results in 20 minutes. Implications for practice, as well as future applications of this technology, are discussed in this article. |
|---|